All In Biotech

Drug Trial Radar · NCT00781391

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)

Last checked: Nov 20, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 21,105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

21,105

Actual

Start

Nov 2008

Primary completion

Apr 2013

Study completion May 2013

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
The TIMI Study Group
First posted
Oct 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, \& Warfarin. The expected duration of the study is 24 months.

Conditions

  • Stroke
  • Atrial Fibrillation
  • Embolism

Interventions

  • warfarin tabletsDrug

    Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months

  • Edoxaban tablets (high dose regimen-60mg)Drug

    Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months

  • Edoxaban tablets (low dose regimen-30mg)Drug

    Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months

  • placebo warfarinDrug

    placebo warfarin

  • placebo edoxabanDrug

    placebo edoxaban

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
  2. Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
  3. Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
  4. Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
  5. Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Locations

1,009 sites in 46 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Glendale, Arizona

  • Site not named

    Lake Havasu City, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Harrisburg, Arkansas

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Alhambra, California

  • Site not named

    Anaheim, California

  • Site not named

    Burbank, California

  • Site not named

    Chula Vista, California

  • Site not named

    Encinitas, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Glendale, California

  • Site not named

    Healdsburg, California

  • Site not named

    Lakewood, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Alamitos, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Banos, California

  • Site not named

    Mather, California

  • Site not named

    Merced, California

  • Site not named

    Newport Beach, California

  • Site not named

    Oceanside, California

  • Site not named

    Pacific Palisades, California

  • Site not named

    Palm Springs, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Redondo Beach, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Torrance, California

  • Site not named

    Ventura, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

Showing 40 of 1,009 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.